

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Giovanni Monteleone

Application No.: 10/551,643

Confirmation No.: 5446

Filed: July 24, 2006

Art Unit: 1635

For: ANTISENSE OLIGONUCLEOTIDES (ODN)
AGAINST SMAD7 AND USES IN
MEDICAL FIELD THEREOF

Examiner: K. Chong

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2). The following references are being submitted in parts due to their voluminous nature: B11, B12, B15, B16, B21, B27, and B29.

In addition, Applicants wish to inform the Examiner about the following co-pending patent application and the content of its file wrapper, including all Office actions issued therein:

Examiner Initials	Our Docket No.	Serial No.	Title	Filing Date	Status	Document Enclosed
	GIU-001CPDV	12/264,058	Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field	11/03/2008	Pending	No
Date Considered:				Examiner's Name:		

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 07-1700, under Order No. GIU-001.

Dated: April 27, 2009

Respectfully submitted,

/Charlene A. Stern-Dombal/
Charlene A. Stern-Dombal
Registration No.: 57,961
GOODWIN PROCTER LLP
Exchange Place
Boston, Massachusetts 02109
(617) 570-8382
Attorney for Applicant